Drug Monograph
Actemra (Tocilizumab)
tocilizumab — humanized monoclonal antibody
Pharmacokinetic Profile
Half-Life
Up to 11 days (4 mg/kg IV); up to 13 days (8 mg/kg IV)
Metabolism
Proteolytic degradation (non-CYP); linear + nonlinear CL
Bioavailability (SC)
~80%
Volume of Distribution
6.4 L (RA); 7.5 L (GCA)
Protein Binding
Not applicable (mAb)
Clinical Information
Drug Class
IL-6 Receptor Antagonist (biologic DMARD)
Available Forms
IV: 80 mg, 200 mg, 400 mg vials; SC: 162 mg/0.9 mL PFS & autoinjector
Route
IV infusion (60 min) or SC injection
Renal Adjustment
Mild-moderate: none needed; severe: not studied
Hepatic Adjustment
Not recommended in active hepatic disease
Pregnancy
May cause fetal harm (animal data)
Lactation
Unknown excretion; weigh risk-benefit
Schedule
Prescription only (not scheduled)
Generic / Biosimilar
Yes — tocilizumab-aazg (Tyenne), tocilizumab-bavi (Tofidence), tocilizumab-anoh (Avtozma)
Black Box Warning
Yes — Serious Infections
Approved Indications & Off-Label Uses
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Rheumatoid arthritis (RA) | Adults with moderately to severely active RA, inadequate response to ≥1 DMARD | Monotherapy or combination with MTX/non-biologic DMARDs | FDA Approved |
| Giant cell arteritis (GCA) | Adults | With tapering glucocorticoids or monotherapy after steroid discontinuation | FDA Approved |
| Systemic sclerosis-associated ILD (SSc-ILD) | Adults | Monotherapy (SC only) | FDA Approved |
| Polyarticular juvenile idiopathic arthritis (PJIA) | ≥2 years old | Monotherapy or with MTX | FDA Approved |
| Systemic juvenile idiopathic arthritis (SJIA) | ≥2 years old | Monotherapy or with MTX | FDA Approved |
| CAR T cell-induced cytokine release syndrome (CRS) | Adults & pediatric ≥2 years | Alone or with corticosteroids (IV only) | FDA Approved |
| COVID-19 (hospitalized) | Adults receiving systemic corticosteroids and supplemental O2, MV, or ECMO | Single IV dose; second dose if needed (IV only) | FDA Approved |
Tocilizumab occupies a unique niche as the first IL-6 receptor antagonist with FDA-approved indications spanning autoimmune rheumatic diseases, vasculitis, interstitial lung disease, oncology-related cytokine storm, and infectious disease. In RA, its ability to be used as monotherapy distinguishes it from many biologics that require concomitant methotrexate for optimal efficacy. The GCA approval represented a landmark, providing the first steroid-sparing biologic for this condition.
Notable Off-Label Uses
Castleman disease (multicentric): Used as an alternative subsequent therapy. Approved in Japan; supported by NCCN category 2A recommendation. Evidence quality: Moderate.
Acute graft-versus-host disease (steroid-refractory): Additional therapy in conjunction with systemic corticosteroids. NCCN category 2A recommendation. Evidence quality: Moderate.
BiTE therapy-induced CRS: Extrapolated from CAR-T CRS data; clinical experience supports efficacy. Evidence quality: Low.
Dosing by Clinical Scenario
Adult Indications
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| RA — IV, combination with DMARDs or monotherapy | 4 mg/kg IV q4wk | 8 mg/kg IV q4wk | 800 mg per infusion | Increase based on clinical response Reduce from 8 to 4 mg/kg for lab abnormalities |
| RA — SC, body weight <100 kg | 162 mg SC q2wk | 162 mg SC qwk | 162 mg weekly | Increase frequency based on clinical response Reduce frequency for lab abnormalities |
| RA — SC, body weight ≥100 kg | 162 mg SC qwk | 162 mg SC qwk | 162 mg weekly | Start at weekly dosing for adequate exposure in heavier patients |
| GCA — IV, with steroid taper | 6 mg/kg IV q4wk | 6 mg/kg IV q4wk | 600 mg per infusion | Can continue as monotherapy after glucocorticoid discontinuation |
| GCA — SC, with steroid taper | 162 mg SC qwk | 162 mg SC qwk | 162 mg weekly | Q2wk may be prescribed based on clinical considerations Can use as monotherapy after steroid discontinuation |
| SSc-ILD — SC only | 162 mg SC qwk | 162 mg SC qwk | 162 mg weekly | IV route not approved for SSc-ILD ACTPen autoinjector not studied for this indication |
| COVID-19 — hospitalized, on systemic steroids + O2 | 8 mg/kg IV × 1 dose | Optional 2nd dose ≥8 h after first | 800 mg per infusion | IV only; SC not approved for COVID-19 Second dose only if no clinical improvement |
| CRS (severe/life-threatening, CAR T cell-induced) | ≥30 kg: 8 mg/kg IV; <30 kg: 12 mg/kg IV | Up to 3 additional doses (≥8 h apart) | 800 mg per infusion; max 4 total doses | IV only; SC not approved Alone or with corticosteroids |
Pediatric Indications
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| PJIA (≥2 yr) — IV, ≥30 kg | 8 mg/kg IV q4wk | 8 mg/kg IV q4wk | Per weight | Alone or with MTX Dilute in 100 mL NS |
| PJIA (≥2 yr) — IV, <30 kg | 10 mg/kg IV q4wk | 10 mg/kg IV q4wk | Per weight | Higher mg/kg needed due to faster clearance Dilute in 50 mL NS |
| PJIA (≥2 yr) — SC, ≥30 kg | 162 mg SC q2wk | 162 mg SC q2wk | 162 mg q2wk | Fixed dose regardless of weight within group |
| PJIA (≥2 yr) — SC, <30 kg | 162 mg SC q3wk | 162 mg SC q3wk | 162 mg q3wk | Less frequent dosing for lower weight |
| SJIA (≥2 yr) — IV, ≥30 kg | 8 mg/kg IV q2wk | 8 mg/kg IV q2wk | Per weight | Note: q2wk dosing (more frequent than PJIA) |
| SJIA (≥2 yr) — IV, <30 kg | 12 mg/kg IV q2wk | 12 mg/kg IV q2wk | Per weight | Highest weight-based dose across all indications Dilute in 50 mL NS |
| SJIA (≥2 yr) — SC, ≥30 kg | 162 mg SC qwk | 162 mg SC qwk | 162 mg weekly | Weekly dosing mirrors adult RA SC frequency |
| SJIA (≥2 yr) — SC, <30 kg | 162 mg SC q2wk | 162 mg SC q2wk | 162 mg q2wk | Less frequent than ≥30 kg group |
Clinical Pearl: Dosing Nuances
The IV dose ceiling is 800 mg for RA, CRS, and COVID-19, but only 600 mg for GCA. Weight-based dosing means patients over 100 kg reach the cap sooner, potentially receiving sub-therapeutic exposure. For RA patients transitioning from IV to SC, administer the first SC dose at the time the next IV dose would have been due. Avoid concomitant biological DMARDs (TNF inhibitors, IL-1R antagonists, anti-CD20 agents) due to compounded immunosuppression risk.
Pharmacology
Mechanism of Action
Tocilizumab is a recombinant humanized IgG1-kappa monoclonal antibody (molecular weight ~149 kDa) that binds with high affinity to both soluble and membrane-bound forms of the interleukin-6 receptor (IL-6R). By occupying the IL-6 binding site on IL-6R, tocilizumab prevents dimerization of IL-6R with the signal-transducing glycoprotein 130 (gp130), thereby blocking downstream activation of the JAK-STAT and MAPK signaling cascades. This results in suppression of acute-phase reactant synthesis (CRP, serum amyloid A, fibrinogen), normalization of haematologic parameters driven by IL-6 excess, and attenuation of B-cell hyperactivity, T-cell differentiation, and synovial inflammation. In RA, IL-6 drives both systemic features (fatigue, anaemia, elevated ESR) and local joint destruction. In GCA, IL-6 sustains vascular inflammation and the granulomatous response. In CRS, the cytokine storm is driven substantially by IL-6, making receptor blockade rapidly effective at resolving fever and haemodynamic instability.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | SC bioavailability ~80%; Tmax ~3 days (SC qwk), ~4.5 days (SC q2wk) | SC provides sustained exposure without infusion visits; adequate for chronic indications. IV preferred for acute indications (CRS, COVID-19) requiring rapid onset. |
| Distribution | Vd,ss: 6.4 L (RA), 7.5 L (GCA), 4.0 L (SJIA/PJIA); central Vd: 3.5 L | Low Vd consistent with monoclonal antibody largely confined to plasma and interstitial fluid. Pediatric patients have proportionally smaller Vd, requiring weight-stratified dosing. |
| Metabolism | Catabolism via proteolytic degradation; dual linear + nonlinear (Michaelis-Menten) elimination driven by IL-6R saturation | At low concentrations, target-mediated clearance dominates (faster elimination). At therapeutic concentrations, receptors saturate and linear clearance predominates. This explains concentration-dependent half-life ranging from ~6 days to 18 days. |
| Elimination | t½: up to 11 days (4 mg/kg IV), up to 13 days (8 mg/kg IV), up to 5 days (162 mg SC q2wk); linear CL ~0.2 L/day (~9 mL/h) | Long half-life at therapeutic doses supports q4wk IV and qwk SC dosing intervals. After discontinuation, CYP450 normalization effects may persist for weeks. |
Side Effects
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Upper respiratory tract infection | 8% (IV+DMARD) | Most common infection; generally mild and self-limiting |
| Injection site reactions (SC) | 10.1% (SC qwk) | Erythema, pruritus, pain; mild severity; rotate injection sites. Higher rates in pediatric SJIA patients (41%) |
| ALT elevation (>ULN to 3×ULN) | 48% (8 mg/kg+DMARD) | Higher incidence with concomitant hepatotoxic agents such as MTX; generally transient and reversible with dose adjustment |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nasopharyngitis | 6% | Reflects immunosuppression; advise patients on infection prevention |
| Headache | 5% (8 mg/kg IV) | May occur during or within 24 h of infusion; usually self-limiting |
| Hypertension | 4–6% | Monitor blood pressure; may occur acutely during infusion (1%) or develop gradually |
| ALT elevation (>3× to 5×ULN) | 5% (8 mg/kg+DMARD) | Requires dose interruption; modify concomitant hepatotoxic agents first |
| Neutropenia (ANC <1000/mm³) | 3.4% (8 mg/kg) | Usually occurs within first 8 weeks; not clearly associated with serious infection risk |
| Hypercholesterolaemia (total cholesterol >240 mg/dL, sustained) | ~19% (SC) | LDL, HDL, and triglycerides all increase; manage per lipid guidelines. Responds to statins. |
| Bronchitis | 3% | Part of the broader infection profile; monitor in elderly or immunocompromised |
| Rash | 3% | Generally mild; distinguish from hypersensitivity reaction |
| Dizziness | 3% | More common at higher doses |
| Thrombocytopenia (platelets <100,000/mm³) | 1.7% (8 mg/kg) | Not associated with serious bleeding events in clinical trials |
Serious
Serious Adverse Effects (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Serious infections (pneumonia, UTI, cellulitis, sepsis, herpes zoster) | 3.6–5.3 per 100 pt-yr | Any time during therapy | Hold tocilizumab immediately; initiate antimicrobials; do not resume until infection is controlled |
| Tuberculosis (pulmonary or extrapulmonary) | 0.1% (worldwide clinical program) | Months to years | Screen before initiation (TST or IGRA); treat latent TB before starting; monitor throughout |
| Gastrointestinal perforation | 0.26 per 100 pt-yr | Variable; primarily as complication of diverticulitis | Urgent surgical evaluation; discontinue tocilizumab. Use caution in patients with diverticular disease or concomitant NSAIDs/corticosteroids. |
| Hepatotoxicity (severe, including liver transplant/death) | Rare | Months to years after initiation | Discontinue if ALT/AST >5×ULN; investigate etiology; do not rechallenge without alternative explanation |
| Anaphylaxis / severe hypersensitivity | 0.1–0.2% (IV); 0.7% (SC) | Usually 2nd–4th infusion; can occur at any time | Stop infusion immediately; manage anaphylaxis per protocol; permanently discontinue |
| Severe neutropenia (ANC <500/mm³) | 0.3–0.4% | Within first 8 weeks | Discontinue tocilizumab; monitor for infection |
| Macrophage activation syndrome (SJIA) | ~3% (open-label SJIA trial) | Variable | Interrupt or discontinue tocilizumab; initiate MAS-directed therapy; note that IL-6 blockade may mask laboratory signs of MAS (CRP suppression) |
| DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) | Very rare (post-marketing) | Weeks to months | Permanently discontinue; hospitalize and treat per dermatology guidance |
Discontinuation
Discontinuation Rates
Adults (RA, IV, 24 weeks)
5% vs 3% placebo
Top reasons: Elevated hepatic transaminases (protocol-driven), serious infections
Adults (RA, SC, 6 months)
0.7% (hypersensitivity-related)
Top reasons: Hypersensitivity reactions requiring discontinuation
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Elevated hepatic transaminases | Most common cause | Often protocol-mandated rather than clinically indicated; many patients can resume at lower dose |
| Serious infection | Second most common | Resumption only after infection controlled and clinical reassessment of risk-benefit |
| Hypersensitivity / anaphylaxis | 0.1–0.7% | Permanent discontinuation required for anaphylaxis; generalized urticaria/rash warrants discontinuation |
Managing Hepatotoxicity: The Most Common Dose-Limiting Toxicity
Transaminase elevations are the most clinically relevant routine adverse effect and the leading cause of dose adjustment. They are more frequent when tocilizumab is combined with methotrexate or other hepatotoxic DMARDs. For ALT/AST 1–3×ULN, first modify concomitant DMARDs, then reduce tocilizumab dose or frequency if persistent. For 3–5×ULN, hold tocilizumab until below 3×ULN. For above 5×ULN, discontinue permanently. Serious hepatic injury, including cases resulting in liver transplant and death, has been reported in post-marketing surveillance.
Drug Interactions
Tocilizumab itself is not metabolized by cytochrome P450 enzymes. However, IL-6-driven inflammation suppresses CYP450 enzyme expression in the liver. When tocilizumab normalizes IL-6 signaling, CYP450 activity is restored toward normal levels, potentially increasing the metabolism of co-administered CYP substrates. This is particularly relevant for drugs with narrow therapeutic indices. The effect may persist for weeks after stopping tocilizumab.
Major
Other Biologic DMARDs (TNF inhibitors, abatacept, rituximab, anakinra)
MechanismAdditive immunosuppression
EffectSubstantially increased risk of serious infection with no established additional efficacy benefit
ManagementAvoid concomitant use; this is a labeled contraindication for combination
FDA PI
Major
Live Vaccines
MechanismImmunosuppression may enable replication of live attenuated organisms
EffectPotential for vaccine-strain infection; also reduced immunogenicity
ManagementAdminister all live vaccines before initiating tocilizumab; follow immunisation guidelines for immunosuppressive agents
FDA PI
Moderate
Warfarin
MechanismIL-6 inhibition restores CYP1A2/2C9 activity, increasing warfarin metabolism
EffectReduced warfarin exposure and potentially sub-therapeutic INR
ManagementMonitor INR closely upon initiation and discontinuation of tocilizumab; adjust warfarin dose as needed
FDA PI
Moderate
Simvastatin, Atorvastatin, Lovastatin
MechanismRestored CYP3A4 activity increases statin metabolism
EffectSimvastatin exposure decreased by up to 57% one week after a single tocilizumab dose; clinical significance uncertain but potentially reduces statin efficacy
ManagementMonitor lipid levels; statin dose adjustment may be needed when starting or stopping tocilizumab
FDA PI (in vivo study)
Moderate
Cyclosporine, Theophylline
MechanismCYP3A4 and/or CYP1A2 restoration increases drug clearance
EffectDecreased serum concentrations of these narrow-TI drugs
ManagementPerform therapeutic drug monitoring upon initiation or discontinuation of tocilizumab; adjust doses accordingly
FDA PI
Moderate
Oral Contraceptives
MechanismCYP3A4-mediated metabolism of ethinyl estradiol increased
EffectPotentially reduced contraceptive efficacy
ManagementCounsel patients regarding back-up contraception during initial tocilizumab use; effect may persist weeks after stopping
FDA PI
Moderate
Omeprazole
MechanismRestored CYP2C19 and CYP3A4 activity
EffectOmeprazole exposure decreased by up to 28% one week after a single tocilizumab dose
ManagementClinical significance likely limited; monitor for symptom recurrence in patients requiring maximal acid suppression
FDA PI (in vivo study)
Minor
Methotrexate
MechanismNo clinically significant pharmacokinetic interaction in either direction
EffectMTX exposure unaffected by tocilizumab at 10 mg/kg single dose with MTX 10–25 mg weekly; tocilizumab clearance unaffected by MTX
ManagementNo dose adjustment needed; safe to co-administer. However, combined hepatotoxicity risk requires closer liver monitoring.
FDA PIMonitoring
-
Liver Panel (ALT, AST, ALP, bilirubin)
Baseline; q4–8wk for first 6 months; then q3 months
Routine More frequent monitoring (q2–4wk) for SJIA. Discontinue if ALT/AST >5×ULN. Do not initiate if ALT/AST >1.5×ULN (except COVID-19, threshold >10×ULN). Investigate symptoms of liver injury promptly (fatigue, anorexia, jaundice, dark urine). -
Neutrophil Count (ANC)
Baseline; q4–8wk for first 6 months; then q3 months
Routine Do not initiate if ANC <2000/mm³ (RA/GCA/SSc-ILD) or <1000/mm³ (COVID-19). Hold if ANC 500–1000; resume when >1000. Discontinue if ANC <500. -
Platelet Count
Baseline; q4–8wk for first 6 months; then q3 months
Routine Do not initiate if platelets <100,000/mm³ (RA/GCA/SSc-ILD) or <50,000/mm³ (COVID-19). Hold if 50,000–100,000; discontinue if <50,000. -
Lipid Panel
Baseline; at 4–8 weeks; then per lipid guidelines
Routine Increases in total cholesterol, LDL, HDL, and triglycerides are expected. Manage per NCEP or cardiovascular risk guidelines. Statins are effective but be aware of reduced statin exposure via CYP3A4 restoration. -
TB Screening
Baseline (TST or IGRA); ongoing clinical vigilance
Routine Treat latent TB before starting tocilizumab. Monitor for active TB even if initial screen is negative. Not required before use for COVID-19. -
Signs of Infection
Every visit; patient education on self-monitoring
Routine IL-6 blockade suppresses CRP and fever, which can mask typical infection signs. Maintain high index of suspicion. Hold drug for serious infections. -
Hepatitis B Reactivation
Baseline screening; if positive, per hepatology guidance
Trigger-based Patients screening positive for HBV were excluded from clinical trials. Screen before starting; if HBsAg positive, consult hepatology for antiviral prophylaxis. -
Demyelinating Symptoms
Ongoing clinical assessment
Trigger-based MS and CIDP reported rarely. Monitor for new neurologic symptoms; use caution in patients with pre-existing demyelinating disorders. -
GI Perforation Symptoms
Ongoing; heightened vigilance in at-risk patients
Trigger-based Evaluate new-onset abdominal symptoms promptly, especially in patients with diverticular disease, concurrent NSAIDs, or corticosteroids.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to tocilizumab or any excipient
- Active serious infection, including localized infections — do not initiate or continue therapy
- Active hepatic disease or hepatic impairment (not recommended)
Relative Contraindications (Specialist Input Recommended)
- Chronic or recurrent infections — requires documented risk-benefit discussion before initiating
- History of diverticulitis or risk factors for GI perforation — weigh risk against benefit; consider gastroenterology input
- Pre-existing cytopenias: ANC <2000/mm³, platelets <100,000/mm³, or ALT/AST >1.5×ULN — these are thresholds below which initiation is not recommended
- Pre-existing or recent-onset demyelinating disorder (MS, CIDP) — uncertain risk; specialist neurology co-management advised
- Hepatitis B carriers — risk of viral reactivation; hepatology consultation for antiviral prophylaxis before starting
Use with Caution
- Elderly patients (≥65 years) — higher incidence of serious infections; closer monitoring recommended
- Patients with history of tuberculosis exposure or residence in endemic areas
- Patients receiving concomitant hepatotoxic drugs (MTX, leflunomide) — more frequent liver monitoring required
- Patients at cardiovascular risk — monitor lipid parameters and manage hyperlipidaemia
- Pregnancy — animal data show embryo-fetal toxicity at doses ≥1.25× MRHD; IgG1 antibodies cross the placenta in the third trimester, potentially affecting neonatal immune responses
FDA Boxed Warning
Risk of Serious Infections
Patients receiving tocilizumab are at increased risk for developing serious infections that may lead to hospitalisation or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt tocilizumab until the infection is controlled. Infections include active tuberculosis (pulmonary or extrapulmonary), invasive fungal infections (candidiasis, aspergillosis, pneumocystis), and bacterial, viral, and other opportunistic infections. Test for latent TB before initiation (except for COVID-19 indication); treat latent TB before starting. Monitor all patients for active TB during treatment, even if initial test was negative.
Patient Counselling
Purpose of Therapy
Tocilizumab works by blocking the interleukin-6 pathway, which drives inflammation in conditions such as rheumatoid arthritis and giant cell arteritis. It does not cure these conditions but can significantly reduce symptoms, prevent joint damage, spare steroid use, and improve quality of life. In cytokine release syndrome, it works rapidly to reverse the dangerous inflammatory cascade.
How to Take
IV infusions are given in a healthcare setting over 60 minutes, typically every 2 or 4 weeks depending on the indication. SC injections can be self-administered at home after proper training, using a prefilled syringe or autoinjector. Rotate injection sites and store prefilled devices in the refrigerator. Allow the syringe to reach room temperature before injecting. Do not shake the device.
Infection Risk
Tell patient
This medicine lowers your immune system’s ability to fight infections. Wash hands frequently, avoid people who are sick, and keep up with recommended vaccinations (no live vaccines while on treatment). Fever and CRP may be suppressed, so be alert for subtle infection signs such as fatigue, chills, cough, or burning with urination.
Call prescriber
Any fever, persistent cough, painful or frequent urination, unusual fatigue, wound that does not heal, or feeling generally unwell. Do not wait — infections require prompt evaluation.
Injection Site Reactions (SC)
Tell patient
Redness, itching, or mild pain at the injection site is common and usually resolves without treatment. Rotate injection sites each time. Apply a cold compress if needed.
Call prescriber
If redness, swelling, or pain at the injection site is severe, spreading, or accompanied by warmth and fever suggesting cellulitis.
Liver Effects
Tell patient
Regular blood tests are needed to check liver function, especially in the first 6 months. Avoid excessive alcohol. If you take other medications that affect the liver, your doctor will monitor more frequently.
Call prescriber
Yellowing of the eyes or skin, dark urine, unusual fatigue, loss of appetite, or pain in the right upper abdomen.
Abdominal Symptoms
Tell patient
Although rare, tocilizumab has been associated with tears in the intestinal wall, particularly in patients with a history of diverticulitis. Report any new abdominal pain promptly.
Call prescriber
Sudden or severe abdominal pain, fever with abdominal tenderness, or any change in bowel habits accompanied by pain.
Allergic Reactions
Tell patient
Serious allergic reactions, including anaphylaxis, can occur. For IV infusions, you will be monitored in the healthcare setting. For SC injections at home, be aware of signs of allergic reaction.
Call prescriber
Difficulty breathing, swelling of the face/lips/tongue, widespread rash or hives, chest tightness, or dizziness after injection — seek emergency care immediately.
Cholesterol Changes
Tell patient
Tocilizumab can raise cholesterol levels. Your doctor will check lipids after starting treatment and may prescribe a statin or adjust an existing statin dose.
Call prescriber
No immediate symptoms to watch for, but attend scheduled blood tests to ensure lipid levels are managed.
Sources
Regulatory (PI / SmPC)
- ACTEMRA (tocilizumab) injection, for intravenous or subcutaneous use. Full Prescribing Information. Genentech, Inc. Revised 09/2024. FDA Label Primary source for all approved indications, dosing, warnings, adverse reactions, and pharmacokinetic data cited in this monograph.
- TYENNE (tocilizumab-aazg) injection. Full Prescribing Information. Fresenius Kabi. 2024. FDA Label First tocilizumab biosimilar with both IV and SC formulations approved in the US (2024).
- European Medicines Agency. RoActemra (tocilizumab) Summary of Product Characteristics. EMA European regulatory reference; covers Castleman disease indication approved in select markets.
Key Clinical Trials
- Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317-328. doi:10.1056/NEJMoa1700199 The GiACTA trial establishing tocilizumab as the first steroid-sparing biologic for GCA with 56% sustained remission at week 52 versus 14% placebo.
- RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645. doi:10.1016/S0140-6736(21)00676-0 Large platform trial (n=4116) demonstrating mortality benefit of tocilizumab in hospitalised COVID-19 patients receiving systemic corticosteroids.
- Burmester GR, Rubbert-Roth A, Cantagrel A, et al. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA (SUMMACTA study). Ann Rheum Dis. 2014;73(1):69-74. doi:10.1136/annrheumdis-2013-203523 Non-inferiority trial establishing SC tocilizumab 162 mg weekly as non-inferior to IV 8 mg/kg q4wk for RA.
- De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385-2395. doi:10.1056/NEJMoa1112802 Pivotal SJIA trial demonstrating JIA ACR30 response in 85% of tocilizumab-treated patients versus 24% placebo at 12 weeks.
- Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (focuSSced). Lancet Respir Med. 2020;8(10):963-974. doi:10.1016/S2213-2600(20)30318-0 Phase 3 trial supporting SSc-ILD approval by demonstrating preservation of lung function (FVC) at 48 weeks.
Guidelines
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924-939. doi:10.1002/acr.24596 Positions tocilizumab as a recommended biologic for RA patients with inadequate DMARD response, with conditional preference for monotherapy capability.
- Maz M, Chung SA, Engel ER, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73(8):1349-1365. doi:10.1002/art.41774 Conditionally recommends tocilizumab for all patients with new-onset or relapsing GCA over glucocorticoid monotherapy.
Mechanistic / Basic Science
- Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731-1740. doi:10.1016/j.intimp.2005.05.010 Foundational mechanistic study demonstrating tocilizumab’s selectivity for IL-6R over related family members (IL-11R, CNTFR, LIFR).
Pharmacokinetics / Special Populations
- Levi M, Grange S, Frey N. Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J Clin Pharmacol. 2017;57(4):459-468. doi:10.1002/jcph.826 Population PK analysis establishing SC bioavailability of 79.5% and body weight as the key covariate influencing tocilizumab exposure.
- Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab. Blood. 2008;112(10):3959-3964. doi:10.1182/blood-2008-05-155846 Explains the transient IL-6 rise after tocilizumab administration and validates the “bathtub theory” of IL-6R blockade pharmacodynamics.